Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. demonstrated strong performance in its recent quarterly results, with a top-line revenue of $191.8 million for 3Q25, reflecting a 10% sequential increase and a 5% year-over-year growth, driven by robust sales of Baqsimi and Primatene Mist. The company anticipates sustained growth, forecasting high-single digit unit growth for Baqsimi in 2025 and a return to double-digit growth in 2026, highlighting a positive trajectory despite some challenges in glucagon and epinephrine sales. Additionally, Amphastar is optimistic about upcoming product approvals and launches, specifically AMP-015 and AMP-007, expected in the first half of 2026, which could further bolster its market position and revenue streams.

Bears say

Amphastar Pharmaceuticals Inc. is facing a negative outlook due to significant decreases in sales expectations for key products, particularly iron sucrose and glucagon, driven by increased competition and supply issues. The anticipated revenue from iron sucrose has been notably lowered from an annual expectation of $60 million to approximately $20 million, while glucagon sales are projected to fall below $70 million starting in 2026, influenced by new market entrants. Additionally, expectations for robust top-line growth have been moderated, with forecasts shifting from double-digit growth in 2026 to a more subdued range of high-single to low-double digits, reflecting concerns about the company's current pipeline and market positioning.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.